文献速递瓣膜外科

风湿性二尖瓣手术中同期房颤消融的临床获益

Concomitant ablation of atrial fibrillation in rheumatic mitral valve surgery.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-10-03

该回顾性队列纳入1997至2016年1229例风湿性二尖瓣病合并房颤的连续患者,其中812例接受同期房颤消融,417例仅行瓣膜手术;采用逆概率治疗加权减少选择偏倚。消融组5年免于房颤复发率显著更高,且死亡和血栓栓塞事件风险更低,提示同期消融可能带来净临床获益。

要点

  • 消融组5年免于房颤复发率为76.5%±1.8%,显著高于非消融组的5.3%±1.1%。
  • 消融组死亡风险显著降低(HR 0.69,95%CI 0.52-0.93)。
  • 消融组血栓栓塞事件风险显著降低(HR 0.49,95%CI 0.32-0.76)。

核心结论

  • 风湿性二尖瓣手术同期行房颤消融与长期死亡和血栓栓塞事件风险降低相关,可能是合理选择。

研究设计与样本

  • 回顾性队列研究,纳入1997至2016年1229例风湿性二尖瓣病合并房颤连续患者,年龄54.4±11.7岁,女性占68.2%。
  • 812例(66.1%)接受同期房颤消融,417例(33.9%)仅行瓣膜手术,采用逆概率治疗加权减少选择偏倚。

主要发现

  • 5年免于房颤发生率在消融组为76.5%±1.8%,非消融组为5.3%±1.1%(P < .001)。
  • 消融组死亡风险显著低于非消融组(HR 0.69,95%CI 0.52-0.93)。
  • 消融组血栓栓塞事件风险显著低于非消融组(HR 0.49,95%CI 0.32-0.76)。
  • 术后卒中发生与死亡显著相关(HR 3.97,95%CI 2.36-6.69)。
  • 亚组分析显示复合终点风险降低见于机械瓣(n=829;HR 0.53,95%CI 0.39-0.73)、生物瓣(n=239;HR 0.67,95%CI 0.41-1.08)和修复(n=161;HR 0.17,95%CI 0.06-0.52)亚组(交互P = .47)。

临床怎么用

  • 在风湿性二尖瓣手术中,可考虑同期行房颤消融以降低长期死亡和血栓栓塞风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Efficacy of atrial fibrillation ablation in rheumatic mitral valve disease has been regarded inferior to that in nonrheumatic diseases. This study aimed to evaluate net clinical benefits by the addition of concomitant atrial fibrillation ablation in rheumatic mitral valve surgery. METHODS: Among 1229 consecutive patients with atrial fibrillation from 1997 to 2016 (54.4 ± 11.7 years; 68.2% were female), 812 (66.1%) received concomitant ablation of atrial fibrillation (ablation group), and 417 (33.9%) underwent valve surgery alone (no ablation group). Death and thromboembolic events were compared between these groups. Mortality was regarded as a competing risk to evaluate thromboembolic outcomes. To reduce selection bias, inverse probability of treatment weighting methods were performed. RESULTS: Freedom from atrial fibrillation occurrence at 5 years was 76.5% ± 1.8% and 5.3% ± 1.1% in the ablation and no ablation groups, respectively (P < .001). The ablation group had significantly lower risks for death (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.52-0.93) and thromboembolic events (HR, 0.49; 95% CI, 0.32-0.76) than the no ablation group. Time-varying Cox analysis revealed that the occurrence of stroke after surgery was significantly associated with death (HR, 3.97; 95% CI, 2.36-6.69). In subgroup analyses, the reduction in the composite risk of death and thromboembolic events was observed in all mechanical (n = 829; HR, 0.53; 95% CI, 0.39-0.73), bioprosthetic replacement (n = 239; HR, 0.67; 95% CI, 0.41-1.08), and repair (n = 161; HR, 0.17; 95% CI, 0.06-0.52) subgroups (P for interaction = .47). CONCLUSIONS: Surgical atrial fibrillation ablation during rheumatic mitral valve surgery was associated with a lower risk of long-term mortality and thromboembolic events. Therefore, atrial fibrillation ablation for rheumatic mitral valve disease may be a reasonable option.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kim WK, Kim HJ, Kim JB, et al. Concomitant ablation of atrial fibrillation in rheumatic mitral valve surgery. J Thorac Cardiovasc Surg. 2018. PMID: 30901792. doi:10.1016/j.jtcvs.2018.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。